Rasburicase
- Generic Name
- Rasburicase
- Brand Names
- Elitek, Fasturtec
- Drug Type
- Biotech
- CAS Number
- 134774-45-1
- Unique Ingredient Identifier
- 08GY9K1EUO
- Background
Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
- Indication
For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
- Associated Conditions
- Hyperuricemia
Fasturtec TLS Treatment / Prophylysis
- Conditions
- Tumor Lysis Syndrome
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT00651911
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
- Conditions
- HyperuricemiaLeukemiaLymphoma
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT00631579
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
- Conditions
- Tumor Lysis Syndrome
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT00628628
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Rasburicase (Fasturtec) Registration Trial
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT00607152
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
- Conditions
- Hyperuricemia
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT00563771
- Locations
- 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
- Conditions
- Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Drug: cyclosporin-AProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00513474
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00360438
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Rasburicase in Tumor Lysis Syndrome
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 33
- Registration Number
- NCT00302653
- Locations
- 🇧🇷
Sanofi-aventis administrative office, São Paulo, Brazil
Rasburicase for Hyperuricemia
- Conditions
- Nutritional and Metabolic Diseases
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00290992
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
- Conditions
- Tumor Lysis SyndromeCancerHyperuricemia
- Interventions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 280
- Registration Number
- NCT00230178
- Locations
- 🇺🇸
University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸New York Methodist Hospital, Brooklyn, New York, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.